Recent research and clinical evidence showed that SGLT2 inhibitors could reduce the incidence of cardiovascular complications in both T2DM and non-DM patients with high efficacy, thus suggesting the potential role of SGLT2 inhibitors as a treatment of CVD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.